odmj OncoDaily Medical Journal ODMJ 3067-6444 OncoDaily Medical Journal US 6102 10.69690/ODMJ-001-1210-6102 Original Research Survival and Challenges with Multimodal Treatment in Children with Rhabdomyosarcoma - Real Scenario from A Resource-limited Center of Bangladesh Begum Ferdousi Pediatric Hematology and Oncology Department, National Institute of Cancer Research and Hospital, Bangladesh aferdousi02@mail.com https://orcid.org/0000-0002-2144-4837 Yasmin Farida Pediatric Hematology and Oncology Department, National Institute of Cancer Research and Hospital, Bangladesh https://orcid.org/0009-0009-1131-3436 Rahman Rezwana Pediatric Hematology and Oncology Department, National Institute of Cancer Research and Hospital, Bangladesh 10 12 2025 ODMJ-001-1210-6102 Copyright (c) 2025 OncoDaily Medical Journal 2025 OncoDaily Medical Journal Bangladesh childhood rhabdomyosarcoma Rhabdomyosarcoma production-ready-file-url Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995 Apr 15;75(8):2186-95. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973-1996, National Cancer Institute. Bethesda, MD, 1999. Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, Wharam M; Children’s Oncology Group Soft Tissue Sarcoma Committee (formely Intergroup Rhabdomyosarcoma Group) representing the Children’s Oncology Group and the Quality Assurance Review Center. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma–a report from the IRSG. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005 Apr 20;23(12):2618-28. Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol. 2005 Apr 20;23(12):2586-7. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001 May;23(4):215-20. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995 Mar;13(3):610-30. Cecchetto G, Bisogno G, De Corti F, et al. Italian Cooperative Group. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer. 2007 Dec 1;110(11):2561-7. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. Gupta AA, Anderson JR, Pappo AS, et al. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer. 2012 Feb 15;118(4):1130-7. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma–a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003 Jan 1;21(1):78-84. HaDuong JH, Martin AA, Skapek SX, Mascarenhas L. Sarcomas. Pediatr Clin North Am. 2015 Feb;62(1):179-200. Lawrence W Jr, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol. 1987 Jan;5(1):46-54. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group. Pediatric Oncology Group. Cancer. 1997 Sep 15;80(6):1165-70. Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol. 1990 Mar;8(3):443-52. Gartrell J, Pappo A. Recent advances in understanding and managing pediatric rhabdomyosarcoma. F1000Res. 2020 Jul 8;9:F1000 Faculty Rev-685. Walterhouse DO, Pappo AS, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2014 Nov 1;32(31):3547-52. Walterhouse DO, Pappo AS, Meza JL, et al. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer. 2017 Jun 15;123(12):2368-2375. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009 Nov 1;27(31):5182-8. Hawkins DS, Chi YY, Anderson JR, et al. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. Casey DL, Chi YY, Donaldson SS, et al. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children’s Oncology Group. Cancer. 2019 Sep 15;125(18):3242-3248. Bisogno G, De Salvo GL, Bergeron C, et al. European paediatric Soft tissue sarcoma Study Group. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019 Nov;20(11):1566-1575. Weigel BJ, Lyden E, Anderson JR, et al. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2016 Jan 10;34(2):117-22. Schoot RA, Chisholm JC, Casanova M, et al. Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. J Clin Oncol. 2022 Nov 10;40(32):3730-3740. Hadley LG, Rouma BS, Saad-Eldin Y. Challenge of pediatric oncology in Africa. Semin Pediatr Surg. 2012 May;21(2):136-41. Rahman ATM,Begum M, CSH Kibria et al.: Outcome of paediatric rhabdomyosarcoma attended in a tertiary care hospital, Dhaka, Bangladesh. Bangladesh Medical Research Council Bulletin. 2020 Jun 10; 46(1):17-21 Leaphart C, Rodeberg D. Pediatric surgical oncology: management of rhabdomyosarcoma. Surg Oncol. 2007 Nov;16(3):173-85. Lawrence W Jr, Hays DM, Heyn R, Beltangady M, Maurer HM. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg. 1988 Oct;12(5):676-84. Lawrence W Jr, Neifeld JP. Soft tissue sarcomas. Curr Probl Surg. 1989 Nov;26(11):753-827. Hays DM, Lawrence W Jr, Wharam M, et al. Primary reexcision for patients with ‘microscopic residual’ tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg. 1989 Jan;24(1):5-10. Rodeberg DA, Wharam MD, Lyden ER, et al. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer. 2015 Jul 1;137(1):204-11.